ENOCHIAN BIOSCIENCES INC (ENOB) Stock Price, Forecast & Analysis
NASDAQ:ENOB • US29350E1047
ENOB Key Statistics, Chart & Performance
The current stock price of ENOB is 0.7 USD. In the past month the price increased by 47.99%. In the past year, price decreased by -75.52%.
ENOB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to ENOB. When comparing the yearly performance of all stocks, ENOB is a bad performer in the overall market: 96.77% of all stocks are doing better.
ENOB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ENOB. ENOB may be in some trouble as it scores bad on both profitability and health.
ENOB Financial Highlights
Over the last trailing twelve months ENOB reported a non-GAAP Earnings per Share(EPS) of -2. The EPS decreased by -149.93% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
ENOB Forecast & Estimates
ENOB Ownership
ENOB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.43 | 404.235B | ||
| AMGN | AMGEN INC | 16.62 | 204.477B | ||
| GILD | GILEAD SCIENCES INC | 16.97 | 189.501B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.05 | 119.327B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.8 | 83.747B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 50.33 | 43.95B | ||
| INSM | INSMED INC | N/A | 32.227B | ||
| NTRA | NATERA INC | N/A | 29.989B | ||
| BIIB | BIOGEN INC | 12.57 | 28.491B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.3 | 20.499B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ENOB
Company Profile
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
Company Info
ENOCHIAN BIOSCIENCES INC
Century City Medical Plaza, 2080 Century City East
Los Angeles CALIFORNIA 90067 US
CEO: Mark Dybul
Employees: 11
Phone: 14539179840.0
ENOCHIAN BIOSCIENCES INC / ENOB FAQ
What does ENOB do?
Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The firm is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. The Company’s product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer (NK) and gamma delta t-cells (GDT).
What is the stock price of ENOCHIAN BIOSCIENCES INC today?
The current stock price of ENOB is 0.7 USD.
Does ENOB stock pay dividends?
ENOB does not pay a dividend.
How is the ChartMill rating for ENOCHIAN BIOSCIENCES INC?
ENOB has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the market capitalization of ENOB stock?
ENOCHIAN BIOSCIENCES INC (ENOB) has a market capitalization of 40.80M USD. This makes ENOB a Nano Cap stock.
Can you provide the upcoming earnings date for ENOCHIAN BIOSCIENCES INC?
ENOCHIAN BIOSCIENCES INC (ENOB) will report earnings on 2022-12-13, after the market close.